上海凯宝(300039.SZ)：KBZ24020获得《药物临床试验批准通知书》

Core Viewpoint - Shanghai Kaibao (300039.SZ) has recently received the Clinical Trial Approval Notice from the National Medical Products Administration for its drug KBZ24020, which is aimed at treating acute ischemic stroke with phlegm-heat syndrome [1] Group 1 - The drug KBZ24020 is derived from clinical experience and is indicated for clearing heat, relieving fire, resolving phlegm, and reducing turbidity [1] - The specific symptoms targeted by KBZ24020 include hemiplegia, limb numbness, dizziness, irritability, heavy breath, sticky phlegm in the mouth, yellow tongue coating, and constipation with foul odor [1]